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Abstract  
 
The work presented in this thesis was developed in collaboration with a Portuguese 
company, BeyonDevices, devoted to pharmaceutical packaging, medical technology and 
device industry. Specifically, the composition impact and surface modification of two 
polymeric medical devices from the company were studied: inhalers and vaginal 
applicators.   
The polyethylene-based vaginal applicator was modified using supercritical fluid 
technology to acquire self-cleaning properties and prevent the transport of bacteria and 
yeasts to vaginal flora. For that, in-situ polymerization of 2-substituted oxazolines was 
performed within the polyethylene matrix using supercritical carbon dioxide. The cationic 
ring-opening polymerization process was followed by end-capping with N,N-
dimethyldodecylamine. Furthermore, for the same propose, the polyethylene matrix was 
impregnated with lavender oil in supercritical medium.  
The obtained materials were characterized physical and morphologically and the 
antimicrobial activity against bacteria and yeasts was accessed. Materials modified using 
2-substituted oxazolines showed an effective killing ability for all the tested 
microorganisms, while the materials modified with lavender oil did not show antimicrobial 
activity. Only materials modified with oligo(2-ethyl-2-oxazoline) maintain the activity 
during the long term stability. Furthermore, the cytotoxicity of the materials was tested, 
confirming their biocompatibilty.  
Regarding the inhaler, its surface was modified in order to improve powder flowability 
and consequently, to reduce powder retention in the inhaler´s nozzle. New dry powder 
inhalers (DPIs), with different needle’s diameters, were evaluated in terms of internal 
resistance and uniformity of the emitted dose. It was observed that they present a mean 
resistance of 0.06 cmH2O0.5/(L/min) and the maximum emitted dose obtained was 68.9% 
for the inhaler with higher needle´s diameter (2 mm). Thus, this inhaler was used as a 
test and modified by the coating with a commonly-used force control agent, magnesium 
stearate, dried with supercritical carbon dioxide (scCO2) and the uniformity of delivered 
dose tests were repeated. The modified inhaler showed an increase in emitted dose from 
68.9% to 71.3% for lactose and from 30.0% to 33.7% for Foradil. 
Key-words: Polyethylene, oligo(2-oxazoline)s, supercritical CO2, lavender oil, 
antimicrobial activity, self-disinfecting, dry powder inhaler, internal resistance, emitted 
dose, surface modification, powder retention, force control agent.  
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Resumo  
 
O trabalho apresentado nesta tese foi desenvolvido em colaboração com uma empresa 
de Portuguesa, BeyonDevices, dedicada à produção de embalagens farmacêuticas, 
tecnologia médica e indústria de dispositivos. Especificamente, estudou-se o efeito da 
modificação de superfície e composição de dois dispositivos médicos poliméricos da 
empresa: aplicadores vaginais e inaladores.  
O aplicador vaginal de polietileno de alta densidade foi modificado utilizando tecnologia 
de fluídos supercríticos para adquirir propriedades de auto-limpeza e evitar o transporte 
de bactérias e fungos para a flora vaginal. Para isso, foi realizada uma polimerização in-
situ de 2-oxazolinas na matriz do polietileno, utilizando dióxido de carbono supercrítico. 
O processo de polimerização catiónica de abertura de anel foi seguido por uma 
terminação usando N,N-dimetildodecilamina. Além disso, para o mesmo propósito, a 
matriz de polietileno foi impregnada com óleo de alfazema em meio supercrítico.  
Os materiais obtidos foram caracterizados física e morfologicamente, e a atividade 
antimicrobiana contra bactérias e fungos foi avaliada. Materiais modificados usando 
oxazolinas-2-subtituída mostraram-se efetivos na morte de todos os microrganismos 
testados, enquanto os materiais modificados com óleo de alfazema não apresentaram 
atividade antimicrobiana. Apenas os materiais modificados com oligo(2-etil-2-oxazolina) 
mantêm a atividade durante os testes de estabilidade a longo prazo. Além disso, 
estudou-se a citotoxicidade dos materiais, confirmando que todos são biocompatíveis.  
Em relação ao inalador, a sua superfície foi modificada com o objetivo de melhorar a 
fluidez do pó e, consequentemente, reduzir a retenção de pó no bocal dos inaladores. 
Avaliaram-se os novos inaladores de pó seco (DPIs), com diferentes diâmetros de 
agulhas, em termos de resistência interna e uniformidade da dose emitida. Concluiu-se 
que eles apresentam uma resistência média de 0,06 cmH2O0.5/(L/min) e que a máxima 
dose emitida foi de 68,9% para o inalador com maior diâmetro de agulha (2 mm). Assim, 
este inalador foi usado como teste e a superfície modificada com um agente de controlo 
da força vulgarmente utilizado, estearato de magnésio. Secou-se com dióxido de 
carbono supercrítico e repetiram-se estudos de dose emitida. O inalador modificado 
mostrou um aumento na dose emitida de 68,9% para 71,3% para a lactose e de 30,0% 
para 33,7% para Foradil. 
Palavras-chave: Polietileno, oligo(2-oxazolina)s, CO2 supercrítico, óleo de alfazema, 
atividade antimicrobiana, auto-desinfecção, inaladores de pó seco, resistência interna, 
dose emitida, modificação de superfície, retenção de pó, agentes de controlo de forças. 
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Abbreviation list  
 
BF3.Et2O – Boron trifluoride diethyl etherate 
C. albicans – Candida albicans  
CFU – Colony forming cells 
C. glabrata – Candida glabrata 
CROP – Cationic ring-opening polymerization  
DPI – Dry poder inhaler  
DSC – Differential scanning calorimetry 
DUSA – Dose uniformity sampling apparatus  
E. coli – Escherichia coli  
EtOx – Oligo(2-ethyl-oxazoline) 
MeOx – Oligo(2-methyl-oxazoline)  
MgSt – Magnesium stearate  
MHA – Muller-Hinton agar 
MHB – Muller-Hinton broth 
PE – Polyethylene 
POx – Polyoxazolines 
S. aureus – Staphylococcus aureus  
SEM – Scanning electron microscopy  
scCO2 – Supercritical carbon dioxide 
SCFs – Supercritical fluids 
XPS – X-ray photoelectron spectroscopy  
YMB – Yeast mannitol broth 
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Chapter 1: Antimicrobial self-clean of a Vaginal Applicator 
 
1.1. Introduction 
 
This chapter describes the adaptation strategy of this thesis for modification of the 
surface of a vaginal applicator in order to induce self-disinfecting ability, reduce the 
contamination and consequently the risk of bacterial and fungal infection during the 
handling of the vaginal applicator. 
 
1.1.1. Medical devices 
 
The use of medical devices is one of the biggest growing areas of medicine and an 
increasing source of healthcare associated infections (HAIs).1  
Medical device infections are typically related with microbe colonization in devices and 
this contamination mostly happens by inoculation with only a few microorganisms from 
the consumer’s skin or mucous during use.2  
The ability to adhere to materials and promote formation of a biofilm is an important 
feature of the pathogenicity of microorganism involved in contamination. Biofilm 
formation occurs in two phases: a rapid attachment of the microorganism to the surface 
and a prolonged accumulation stage that involves cell proliferation and intracellular 
adhesion. Factors involved in microbial adherence include physicochemical forces as 
polarity, London-van der Waal’s forces and hydrophobic interactions.3 Once adhered to 
the surface, microorganisms multiply and accumulate in multilayered cell clusters, which 
requires intercellular adhesion, chemical interactions or quorum sensing mechanisms.4   
Therefore, improving the bacterial resistance of polymer surfaces is a major goal in the 
development of the medical devices. In order to reduce the frequency and level of 
contamination of surfaces, the use of self-disinfecting surfaces is a promising method.5  
 
 
1.1.2.  Vaginal applicators  
 
Intravaginal drug delivery has been conventionally restricted to the delivery of 
antinfectives to the local vaginal cavity. The vaginal route is a potential way for the 
delivery of therapeutically biological molecules, vaccines and hormones, mostly in the 
field of microbicides, mucosal vaccines and therapeutic proteins and peptides. 
2 
 
Applicators are planned to be introduced in the vagina, effectively deliver the therapeutic 
product, and then be removed (see Figure 1.1).6 
 
 Figure 1.1 BeyonDevices’ Vaginal Applicator.6  
 
The healthy human vagina is dominated by lactobacilli, which plays an important role in 
protecting the host against urogenital infections. Vulvovaginal candidiasis (VVC) is an 
infection of the female genital tract caused by the abnormal growth of yeast-like yeasts. 
VVC is caused mainly by the genus Candida, where 80–90% of cases are due to 
Candida albicans and 10–20% due to the other species called not-C. albicans (Candida 
tropicalis, Candida glabrata, Candida krusei, Candida parapsilosis, Candida 
pseudotropicalis, and Candida lusitaniae). C. glabrata is the second specie most 
frequent in the VVC. The manifestations of VVC are often painful and uncomfortable and 
by affecting millions of women annually, being considered an important global public 
health problem.7 
Urinary tract infections (UTIs) are one of the most frequent clinical bacterial 
contaminations in women, accounting for nearly 25% of all infections. Around 50–60% 
of women will develop UTIs in their lifetimes and Escherichia coli is the organism that 
causes UTIs in most patients. Despite the fact that most E. coli is eradicated by the host 
defense mechanisms within days, only small clusters of intracellular E. coli are observed 
to persist for several months in an antibiotic-resistant state.8 
The self-disinfecting surface of a vaginal applicator can promote the reduction of the risk 
of infections caused by spread of microorganisms from external environment in vaginal 
flora. 
  
 
 
3 
 
1.1.3.  Self-disinfecting surfaces 
 
Innovative technologies have identified new approaches to develop self-disinfecting 
surfaces to minimize HAIs. These include changing the structure or surface to minimize 
the attachment of microbes or to delay the development of biofilms. The surface 
modification with long-term or even permanent antimicrobial activity is one key strategy 
for the provision of improved hygienic living conditions.  
One of the strategies used for surface modification is to increase the surface 
hydrophilicity by grafting polar and hydrophilic groups such as alcohols or ethers and this 
can be performed by plasma treatment9 and/or by grafting hydrophilic polymers.10  
Another strategy consists in the impregnation or coating the surface with heavy metals 
(eg, silver or copper), however the poor biocompatibility of the agents (for example silver 
ions) is a challenge in the design and development of bactericide surfaces.11,12  
Immobilization or impregnation of low molecular weight antibiotics, cationic antimicrobial 
peptides, lysozyme, chitosan and charged polymers on different surfaces has also been 
tested in the development of bactericidal surfaces. The use of antibiotics such as 
penicillin, ampicillin or gentamycin has provided long-term antimicrobial activity and low 
risk of side effects, but inducing bacterial resistance is the downside of this strategy.13 
Antimicrobial peptides (AMPs) are short natural or synthetic peptides which consist of 
less than 50 amino acids, mostly with overall positive charge, and the mechanism to kill 
bacteria is mainly through a cell membrane disruption. The study and use of AMPs is 
increasing due to their broad spectrum antimicrobial activity, speed of action and low 
propensity for developing resistant mutants owing to their mechanism of bacteria killing.14 
Antimicrobial properties are achieved by the immobilization of AMPs to polymer, however 
the conjugation of AMPs may compromise their anti-biofouling properties, once a 
decrease in peptide concentration resulted in an increased non-fouling character with a 
decrease of bactericidal activity, may lead to their poor long-term performance.15 The 
development of bactericidal surfaces with lysozyme and chitosan is valuable and 
emerging, as natural agents are environmentally benign, but the bland bactericidal 
activity of chitosan and its influence on pH may limit its application.16 Charged polymers, 
particularly quaternary ammonium polymers, can make potent antimicrobial coatings, 
however their toxicity and biocompatibility may limit their applications in materials for 
biomedical use.17   
Generally, the death of the bacteria is a result of either bacterial membrane disruption or 
of a specific interaction of the immobilized antibacterial agent with a target biomolecule 
at the surface of the bacteria. 
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1.1.4. Antimicrobial polymers 
 
Antimicrobial polymers are promising substitutes of low-molecular-weight antibiotics, 
environmentally problematic biocides and disinfectants. The majority of antimicrobial 
polymers are amphiphilic polycations, containing quaternary ammonium, phosphonium, 
or thertiary sulfonium groups. These macromolecules can be classified as biocide-
releasing polymers, polymeric biocides and biocidal polymers.18 Macromolecules 
belonging to first two classes are considered biodegradable and mostly release biocides 
that will destroy the vaginal flora. In opposition, biocidal polymers act as one molecule 
that is able to destabilize and eventually destroy the cell membrane of microorganisms 
resulting in cell lysis and cell death.19 Even antibiotic-resistant bacteria such as 
methicillin-resistance Staphylococcus aureus (MRSA) can be killed effectively. Some 
examples of potentially biodegradable biocidal polymers have been described in the past 
few years.20 An alternative to the traditional polymers are biocides coupled as end groups 
to inactive polymers.21 If the polymer contains a second, nonantimicrobially active end 
group mentioned to as a satellite group, the antimicrobial activity of these polymers can 
be controlled. It was shown recently that polyoxazolines with an antimicrobial group are 
antimicrobially active.22  
 
1.1.5.  Poly(2-oxazoline)s 
 
Poly(2-oxazoline)s (POx) constitute a polymer class with exceptional properties and 
great versatility with use in a wide range of biomedical applications and have been 
proposed as a versatile platform for the development of new medicines.23 POx is a 
neutral hydrophilic polymer with non-fouling properties studied for inhibiting bacterial 
adhesion.24 
Polyethylene glycol (PEG) is the most extensive used polymer in biomedicine, being 
used mainly to increase half-life and immunogenicity of proteins.25 Although PEG 
remains the gold-standard in polymer based biomedical applications, based on its low 
polydispersity, biocompatibility and stealth behavior, it has some disadvantages and 
limitations. The polyether backbone of PEG is susceptible to oxidative degradation 
representing strong drawbacks particularly for long term applications as antifouling 
surfaces for implants, as well as possible induction of PEG-mediated complement 
activation has been recently reported.26 
Thus, POx constitutes a probable candidate to overcome the drawbacks of PEG, 
retaining the required features for a polymer used in biomedical applications, such as 
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biocompatibility, stealth behavior, low dispersity, responsiveness, high functionalization 
possibilities, and high versatility attainable by copolymerization.23 Poly(2-methyl-2-
oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline) (PEtOx) have analogous stealth 
behavior as PEG while offering useful properties such as thermo-responsiveness, low 
viscosity and high stability.27 
POx are readily obtained via the cationic ring-opening polymerization (CROP) of 2-
oxazolines (see Figure 1.2). One huge advantage of the cationic ring-opening 
polymerization of 2-oxazoline monomers arises from the fact that they can be 
synthesized in a way that side-reactions such as the termination of chain growth and/or 
chain-coupling are suppressed (because of the control of this type of polymerization, it 
has been described as living polymerization).28  
 
 
Figure 1.2 Reaction scheme to general strategy to synthesize 2-oxazolines (e.g. 2-methyloxazoline) by 
cationic ring-opening polymerization (CROP), yielding a living polymer.29   
 
The living polymers of POx could be end-functionalized with various quaternary 
ammonium groups and the obtained oligomers exhibit antimicrobial activity due to this 
satellite groups. This strategy allow to obtain polymers with antimicrobial activity, low 
cytotoxicity, fast killing rate and broad-spectrum biocidal activity, representing a good 
approach to avoid and overcome bacterial resistance.30  
 
1.1.6. Mechanism of action of end-capped poly(2-oxazoline)s 
 
The biocidal mechanism, of such polymers is still not entirely clear. Such compounds 
have an antimicrobial action if they contain an alkyl chain of adequate length to interact 
with the bacterial membrane by binding to it. Then the membrane’s equilibrium is 
disturbed due to the positive charge of the bioactive function eventually leading to cell 
death (see Figure 1.3).31,32 POx derivatives only show bactericide activity if equipped 
with ammonium compounds that are active as low molecular weight pendants.  
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Figure 1.3 One proposed interaction between an antimicrobial polymer and a Gram-positive bacterium.22 
  
 
1.1.7. Lavender oil  
 
In addition to Pox, essential oils are well recognized in traditional medicine as 
antimicrobial agents and they are characterized by a wide spectrum of activity against 
bacteria and yeasts. 
Lavender oil is well known for its application in aromatherapy, cosmetics, soaps and 
perfumes. Lavender essential oil is usually produced by steam distillation, from both the 
flower heads and foliage, but the chemical composition differs greatly, with the sweeter 
and most aromatic oil being derived from the flowers.33 Today, the pure oil is most often 
used in aromatherapy or incorporated into soaps and other products as a pleasant 
fragrance or as an antimicrobial agent.  
Lavender oil (primarily Lavandula angustifolia) has been found to be active against many 
species of bacteria and yeasts.34 It has also been suggested that essential oils, including 
lavender, may be useful in treating bacterial infections that are resistant to antibiotics. 
For example, L. angustifolia oil has demonstrated to have in vitro activity against both 
MRSA (methicillin-resistant Staphylococcus aureus) and VRE (vancomycin-resistant 
enterococci).35 
Some cases of activity against bacteria and yeasts have been reported in literature, 
which incentive its application in antifouling and antimicrobial materials.36 
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1.1.8.  Supercritical fluids (SCFs) 
 
Supercritical fluids have gained interest as reaction solvent or processing agent. 
Recently, they have been applied in polymerization, swelling, impregnation, 
fractionation, purification and formation of powdered polymers. By definition, SCFs are 
substances at a temperature and pressure higher than their critical values, and which 
have a density close to or higher than its critical density (Figure 1.4 and Figure 1.5).37  
SCFs may be relatively dense and dissolve certain solids while being miscible with 
permanent gases and exhibiting high diffusivity and low viscosity. In addition, SCFs are 
highly compressible and the density dependent properties (and therefore solvent 
properties) can be “tuned” over a wide range by varying pressure.38 
 
Figure 1.4 Schematic pressure-temperature phase diagram for a pure component showing the supercritical 
Fluid (SCF) region.39  
 
 
Figure 1.5 Carbon dioxide density-temperature phase diagram.40 
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In particular supercritical carbon dioxide (scCO2) has been studied extensively for the 
synthesis and processing of polymers. CO2 is naturally occurring, abundant and existing 
in natural reservoirs. In comparison to other substances, CO2 has an easily accessible 
critical point with a critical temperature (Tc) of 31.1 °C and a critical pressure (pc) of 7.38 
MPa. It is an ambient gas, and can be recycled after use. Finally, it is inexpensive and 
non-flammable.41 
CO2 can be separated from a reaction mixture by reducing the pressure, yielding a dry 
polymer product and in one-step process. It is possible the production of materials with 
high purity, since the final depressurization and extraction enables the removal of 
unreacted monomers and initiator from the polymer matrix. Also, it is possible to obtain 
polymers by a relatively simple and inexpensive process. 
SCFs have also been recognized as excellent extraction solvent, due its availability and 
safety being considered as a GRAS (Generally Recognized as Safe) solvent. Such 
advantages make scCO2 a solvent of choice in food and fragrances industry proven by 
coffee decaffeination, hop and essential oil extraction processes.42 
 
 
1.1.9.  scCO2-assisted in-situ polymerization in polyethylene 
 
Polyethylene (PE) is considered the most important and extensively used thermoplastic 
because of its low cost, good processability and several range of applications. However, 
PE has some disadvantages such as low surface energy, lack of chemical functionality, 
difficulty in dyeing and poor compatibility with synthetic polar polymers. The 
characteristics modification of PE has been widely investigated for electrical, coating, 
bonding, and biomedical applications. 
The density of SCFs, and therefore their solvent strength, is tunable from gas to liquid 
by changing pressure and temperature. This offers the ability to control the degree of  
polymers’ swelling, as well as the partitioning of small molecules penetrating between 
swollen polymer and fluid phases.43  The low viscosity and almost inexistent surface 
tension of SCFs allow for rapid mass transfer into a swollen polymer.  
Since the capacity of a solvent to dissolve solutes mainly depends on its density, 
changes in temperature or pressure may significantly change the dissolution properties 
of a supercritical solvent without variation of its composition. Additionally, the viscosity of 
scCO2 is much lower than that of liquid solvents, and also varies strongly with deviations 
in pressure and temperature as stated before. Because of these features, diffusion 
coefficients of monomers and polymers are comparable to those of gases in SCFs. Any 
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small change in temperature or pressure, in particular near the critical point, has a large 
effect on the diffusivities.44 
ScCO2 has been used to impregnate polymers matrices with different additives. Using 
scCO2 as a swelling agent, is possible to develop a synthetic method to produce new 
polymer composites.45 Both the monomer and initiator are dissolved in scCO2, 
impregnated into the polymer substrate, and subsequently polymerized (see Figure 1.6). 
Using this method, it is possible to obtain polymer composites, even when using 
polymers that are immiscible and cannot be obtained through conventional methods.   
 
 
 
Figure 1.6 General representation for the in-situ polymerization in scCO2. The monomer, initiator and 
impregnating-material are placed in a high-pressure cell and the CO2 is added. A supercritical phase occurs, 
the monomer and initiator solubilize and the polymerization starts. After the end of polymerization, the non-
impregnated polymer precipitates and CO2 is released.   
 
In this work, an in-situ polymerization was performed in order to synthesize oligo(2-
oxazoline)s terminated with a quaternary ammonium inside the PE matrix, in scCO2. 
During scCO2 assisted process, PE swells and POx polymerizes inside the PE matrix. 
At the end of the procedure, the reactor is vented, PE returns to its initial form and trapps 
the antimicrobial POx inside its structure.46   
 
1.1.10.  ScCO2-assisted impregnation 
 
The polymer sorption and swelling processes in supercritical media and, in particular in 
scCO2, became recently an area of increasing attention. Swelling and plasticization by 
scCO2 sorption lead to the polymer transition from a glassy state into a rubbery state. In 
a rubbery state, the polymer chains can move more freely, which makes impurity 
extraction and polymer impregnation with additives more efficiently. 
The impregnation process is feasible when the active substance (the solute) is soluble 
in the supercritical fluid, the polymer is swollen by the supercritical solution and the 
partition coefficient is favorable enough to allow the matrix to be charged with enough 
solute (see Figure 1.7).47 
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Figure 1.7 General representation for a scCO2-assisted impregnation. The compound and impregnating-
material are placed in a high-pressure cell and the CO2 is added. A supercritical phase occurs, the compound 
solubilize and the impregnation starts. After depressurization, the non-impregnated polymer precipitates. 
 
In this work, the lavender oil was impregnated in the PE matrix, using scCO2, leading to 
a structure with antimicrobial properties and a characteristic fragrance.  
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1.2. Experimental 
 
1.2.1. Materials 
 
The high density polyethylene was supplied by BeyonDevices and used without further 
purification. The monomers 2-methyl-oxazoline and 2-ethyl-oxazoline, the initiator boron 
trifluoride diethyl etherate (BF3.Et2O) and N,N-dimethyldodecylamine were purchased 
from Sigma-Aldrich. All commercial reagents were used as received. Carbon dioxide was 
supplied by Air Liquide with a purity lighter than 99.998%. Dulbecco's modified Eagle's 
medium (DMEM-F12) and resazurin based in vitro toxicology assay kit were purchased 
from Sigma-Aldrich. Human fibroblast cells (Normal human dermal fibroblasts adult, 
cryopreserved cells) were purchased from PromoCell. Fetal bovine serum (FBS) was 
purchased from Biochrom AG. 
 
1.2.2. Instrumentation  
 
The thermal behavior of the samples was measured using Differential Scanning 
Calorimetry (DSC) in a Perkin Elmer DSC 7. The samples (~12mg) were analyzed under 
a flow of nitrogen gas and taken between 20oC and 200oC at a scan rate of 10 oC/min.  
The morphology of the samples was recorded using Scanning Electron Microscopy 
(SEM) in a Hitachi S-2400 instrument, with an accelerating voltage set to 15 kV. All 
samples were gold coated before analysis. 
X-ray photoelectron spectroscopy (XPS) analysis were performed on a XSAM800 X-ray  
spectrometer, operated in the fixed analyser transmission (FAT) mode, with a pass 
energy of 10  eV, a power of 120 W and using a non-monochromatic radiation (energy 
of 1486.6  eV). Spectra were collected with a step of 0.1 eV, using a Sun SPARC Station 
4 with Vision software (Kratos). The curve fitting for component peaks was carried out 
with a non-linear least-squares algorithm using a commercial program – the 
XPSPEAK41. For the bond energy correction (EL) for accumulated charge, was 
considered the bond energy of bonded carbon only for other carbons and for hydrogen 
of 285 eV. Sensitivity factors used were: C 1s - 0.25, O 1s 0.66, N 1s - 0.42 and Si 2p – 
0.27. 
Elementary analysis was achieved using a FlashEA 1112 Series CHNS Analyzer. The 
tests were performed with the combustion reactor temperature of 900 oC, the GC column 
temperature of 65 oC, the Helium flow rate of 130 ml/min, the oxygen flow rate of 250 
ml/min. The oxygen injection time was 7 s, the sample injection time was 12 s and the 
analysis time was 720 s. The sample and standard height was 2-3 mg. The calibration 
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standard was BBOT [2,5-Bis (5-tert-butyl-benzoxaxol-2-yl) thiophene] 6.51% N, 72.53% 
C, 6.09% H e 7.44% S, with K factor as calibration method. 
 
1.2.3. In-situ polymerization of 2-substituted oxazolines 
 
1.2.3.1. Experimental apparatus 
 
The in-situ polymerization was undertaken in a high-pressure apparatus schematically 
presented in Figure 1.8. The real apparatus is shown on Figure 1.9, Figure 1.10 and 
Figure 1.11.    
 
                   
Figure 1.8 Schematic representation of the experimental apparatus. 1-CO2 cylinder; 2-high pressure pump; 
3-line filter; 4-check valve; 5-high pressure transducer; 6-rupture disk; 7-thermostatted bath; 8-syringe; 9-
HPLC high pressure valve; 10-high-pressure cell, 11-stirrer; 12-shlenk; 13-vent; V1 to V10-high pressure 
valves (adapted from reference29) 
 
 
Figure 1.9 Real experimental apparatus, during the in-situ polymerization.  
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Figure 1.10 Real apparatus of a high-pressure cell.  
 
 
Figure 1.11 Real experimental apparatus, inside the high-pressure cell. 
 
1.2.3.2. Pre-treatment of the PE samples 
 
The polyethylene-based vaginal applicator was cut into similar pieces (~25 mg) and the 
samples were washed with ethanol under stirring overnight. 
  
1.2.3.3. Synthesis of living oligomers 
 
In situ-polymerization reactions were carried out in a 33 ml high-pressure cell. Two 
different 2-substituted oxazoline oligomers were synthesized (MeOx and EtOx) and 
boron trifluoride etherate (BF3.Et2O) was used as initiator. The monomer/initiator ratios 
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used were [M]/[I]=15 (2-methyl-2-oxazoline) and [M]/[I]=12 (2-ethyl-2-oxazoline), 
according with previous studies.29      
The PE samples (~25 mg), the 2-substituted oxazoline and the initiator were placed in a 
high-pressure cell with a magnetic stirring bar, with a physical division between the PE 
samples (see Figure 1.11) and the reagents, and then immersed in a thermostatized oil 
bath. The polymerizations were performed at 115 ºC. The desired pressure of 18 MPa 
was achieved using carbon dioxide pressurized in the high-pressure cell. After 20 h of 
reaction, the living oligomer was obtained and able to be terminated with different 
molecules.     
 
1.2.3.4. End-capping with N,N-dimethyldodecylamine 
 
The termination of living oligomer was performed with addition of a tenfold excess of 
amine in relation to the added amount of initiator,48 using a HPLC high-pressure valve. 
The reaction was maintained at the temperature of polymerization under stirring during 
24 h. After this, the temperature was lowered to 45oC and the oligomer was washed 
using fresh CO2 during 2 h, in order to remove unreacted reagents. The obtained 
samples were placed in ethanol overnight under stirring, in order to remove the oligomer 
adsorbed to the surface (see Figure 1.12).     
 
 
Figure 1.12 Synthesis of oligo(2-methyl-2-oxazoline) end-capped with N,N-dimethyldodecylamine using 
CROP polymerization in scCO2 medium.  
 
1.2.3.5. Impregnation of Lavender oil 
 
PE samples (~25 mg) were impregnated with lavender oil in scCO2 using a high-pressure 
cell. The impregnation was performed at 115 ºC and 18 MPa using an excess of oil. After 
20 h of continuous stirring the high pressure vessel was rapidly depressurized. 
The lavender oil used was extracted using scCO2 in the aim of a doctoral thesis1 at the 
host laboratory and was used in the development of these materials. Composition of 
lavender oil extracted can be found in Appendix 1.   
                                                          
1 Work developed by Pedro Lisboa. Lavender gently offered by Delta S.A.  
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1.2.4. Evaluation of the antimicrobial activity 
 
1.2.4.1. Microorganisms growth conditions  
 
Escherichia coli DH5α (gram-negative bacteria), Staphylococcus aureus ATCC25923 
and Staphylococcus aureus COL MRSA (both gram-positive bacteria) strains were 
grown at 37oC in Mueller-Hinton broth medium (MHB, DIFCO, USA). Candida albicans 
PYCC 3436 and Candida glabrata PYCC2814 (both yeasts) strains were grown at 37oC 
in Yeast Mannitol broth medium (YMB, composition in g/L: Potassium hydrogen 
phosphate 0.5; magnesium sulfate heptahydrate 0.2; sodium chloride 0.2; calcium 
chloride hexahydrate 0.2; mannitol 10; yeast extract 0.4). Cultures grown overnight at 
37oC were diluted in the same media to 105 CFU/mL to carry out the tests referred to 
below. 
 
1.2.4.2. Disc diffusion  
 
This test was performed using the non-impregnated oligomers recovered from the 
bottom of the reactor after the in-situ polymerizations. Cells were cultivated using a swab 
impregnated with a solution of each microorganism (105 cells) in standard growth 
medium, Mueller-Hinton Agar (MHA, DIFCO, USA).  
Oligomers were dissolved in sterile water in a concentration of 100 mg/ml. Lavender oil 
was used without dissolution.  
Paper discs (no. 231039, Becton and Dickinson, USA) were then impregnated with 10 
µl of oligomer solution or lavender oil and placed on the surface of the agar plates 
containing growth medium. A negative control was also performed using a disc 
impregnated with sterile water. The plates were incubated for 24 h at 37oC for bacterial 
strains and 48 h at 37oC for yeast. Experiments were executed in duplicate and after 
incubation the inhibition zone was evaluated.  
 
1.2.4.3. Microdilution  
 
The tests were performed using four different microorganisms referred to above: E. coli, 
S. aureus COL, C. albicans and C. glabrata. One impregnated polyethylene sample (~25 
mg) was placed in each well of a 24-well tissue culture plate, containing 1 ml of medium 
and 5 µl of the microorganism suspension (105 cells), and incubated at 37 °C with 
shaking for 24 h for bacterial strains and 48 h for yeast.  The samples were diluted (10-1 
to 10-8) and 20 µl of selected diluted cultures were plated on MHA for bacterial strains, 
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and Yeast Mannitol Agar (YMA, composition in g/L: Potassium hydrogen phosphate 0.5; 
magnesium sulfate heptahydrate 0.2; sodium chloride 0.2; calcium chloride hexahydrate 
0.2; mannitol 10; yeast extract 0.4; agar 10) for yeasts, and incubated at 37°C for 24 h. 
After this, the number of colonies was determined (colony forming units – CFU/ml) and 
the results were normalized for reduction of the viable cells in log stages (see Figure 
1.13). Experiments were performed in duplicated in two independent assays.   
 
 
Figure 1.13 Schematic representation of the methodology used to evaluate the antimicrobial activity of 
samples. 
 
The long term stability of the samples was evaluated using an Accelerated Aging 
procedure (ASTM F1980). Data obtained from the study is based in the conditions that 
simulate the effects of aging on the materials.  
Accelerated Aging calculation is based on Arrhenius’ equation which simply states that 
a 10 °C increase in temperature doubles the rate of chemical reaction. Four variables 
were used in calculating the accelerated aging test duration: test temperature (Te), 
ambient temperature (Ta), Reaction rate factor (Q10=2 for medical devices) and real-time 
equivalent (DRT).  
 
 
                      𝐴𝐴𝑅(𝐴𝑐𝑐𝑒𝑙𝑒𝑟𝑎𝑡𝑒𝑑 𝐴𝑔𝑔𝑖𝑛𝑔 𝑅𝑎𝑡𝑒) =  𝑄10
((𝑇𝑒−𝑇𝑎)/10)                                       eq. 1 
 
              𝐴𝐴𝑇𝐷(𝐴𝑐𝑐𝑒𝑙𝑒𝑟𝑎𝑡𝑒𝑑 𝐴𝑔𝑔𝑖𝑛𝑔 𝑇𝑖𝑚𝑒 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛) =
𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝑅𝑒𝑎𝑙 𝑇𝑖𝑚𝑒
𝐴𝐴𝑅
                              eq. 2 
 
 
Using equations 1 and 2, it was possible to determine the conditions for the accelerated 
aging test. In this case, the samples were placed at 60 °C during 52 days. After this time, 
the bacteria viability was tested using the same procedure as described before.  
 
 
 
17 
 
1.2.4.4. Bactericidal vs bacteriostatic 
 
Using the mediums from microdiluition test where bacterial growth was not verified, 10 
µl were diluted in 1 ml of new medium and incubated at 37 oC during 24 h. After this time, 
the presence of growing was evaluated. 
 
1.2.5.   Evaluation of the anti-biofouling activity 
 
The samples used in the microdilution tests were washed with PBS and fixed with 
glutaraldehyde (2.5%) during 10 minutes. After that, the samples were washed with 
water, dehydrated with ethanol 70%, 80% and 90% sequentially during 10 minutes and 
stored in ethanol 100%. SEM was used to assess the bacterial adhesion and proliferation 
during the 24 h of the microdilution assay for bacteria or 48h for yeasts.    
 
1.2.6. Biocompatibility tests 
 
1.2.6.1. Polyethylene impregnated with 2-substituted oxazolines 
 
In vitro cytotoxicity assays were performed with cell line HCT-116 (colorectal carcinoma 
cell line) and human fibroblasts through the use the CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (Promega, Madison, USA), a colorimetric method 
for determining the number of viable cells. 
To the maintenance and splitting of the cell line, and at 80 % confluence, cells were 
harvested and centrifuged during 5 minutes. The supernatant was discarded, and the 
cell pellet resuspended in 2 ml of medium. For growth inhibition assays, 0.75x105 
cells/mL were plated into flat bottomed 96-well plates (Costar, Corning, NY) and 
incubated  at 37 oC, 99% humidity and 5% CO2 (v/v). Cell density was evaluated as the 
total number of viable cells within the grids on the hemacytometer (Hirschmann, 
Eberstadt, Germany) using trypan blue exclusion method. For this procedure 350 µl of 
medium was pipetted to a 2 mL eppendorf together with 50 µl of the 2ml cell suspension 
followed by 100 µl of 0.4 % (v/v) trypan blue solution (Sigma). The hemacytometer was 
loaded and examined immediately under the microscope at low resolution, and cell 
viability was determined through the following equation: 
𝑁º 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
𝑚𝑙
=
∑ 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑞𝑢𝑎𝑑𝑟𝑎𝑛𝑡
4
∗ 104 (𝐶ℎ𝑎𝑚𝑏𝑒𝑟 𝑉𝑜𝑙𝑢𝑚𝑒 ∗ 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟)                    eq. 3 
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After 24 h, MeOx and EtOx solutions (0.45 mg/mL), and PE, PE_MeOx and PE_EtOx 
material samples were added (after removal of depleted medium), and the cells were 
incubated for 1 h and 24 h [37 oC, 99% humidity and 5% CO2 (v/v)]. Subsequently a 
reaction mix of medium, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt), and PMS (phenazine methosulfate) (Kit 
Promega) in a ratio of 100:19:1 was added to each well and further incubated for 45 min. 
During this period, MTS is bioreduced into formazan, by dehydrogenase enzymes 
present in metabolically active cells, which in turn is susceptible of being measured at 
490 nm absorbance by Tecan Infinite F200 Microplate Reader (Tecan, Männedorf, 
Switzerland), directly from the 96-well assay plate, so that the quantity of formazan 
product measured is directly proportional to the number of living cells in culture. The cell 
viability results for each concentration were normalized relatively to the control samples 
and obtained accordingly to the following formula: 
𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑏𝑠𝑜𝑟𝑣𝑎𝑛𝑐𝑒 (490 𝑛𝑚)
𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴𝑏𝑠𝑜𝑟𝑣𝑎𝑛𝑐𝑒 (490 𝑛𝑚)
∗ 100 = 𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%)                                         eq. 4 
 
1.2.6.2. Polyethylene impregnated with lavender oil  
 
1.2.6.2.1. Proliferation of human fibroblast cells in the presence of samples 
 
To evaluate cell behavior in the presence of the samples, human fibroblasts cells (4x104 
cells/well) were seeded with materials in a 96-well plate and cultured with DMEM-F12 
supplemented with fetal bovine serum (FBS), for 48 h, at 37°C under a 5% CO2 
humidified atmosphere. Wells containing cells in the culture medium without materials 
were used as negative control. EtOH 96% was also added to some wells and they were 
used as a positive control. Previously to cell seeding, materials were sterilized using UV 
irradiation during 30 minutes. Cell growth was monitored using an Olympus CX41 
inverted light microscope (Tokyo, Japan) equipped with an Olympus SP-500 UZ digital 
camera.49,50,51 
 
1.2.6.2.2. Characterization of the cytotoxic profile of the samples 
 
Human fibroblast cells were seeded, in contact with sterilized materials, at a density of 
4x104 cells/well and cultured with DMEM-F12. Subsequently, the mitochondrial redox 
activity of viable cells was assessed through a resazurin assay (n=5). At 24 and 48 h, 
cells were incubated with 100 µL DMEM-F12 and 10 µL of resazurin 0.1% (w/v) in 5% 
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CO2 humidified incubator, for 24 h, at 37 ºC. Fluorescence of metabolized resazurin was 
measured using a Gemini EM spectrophotometer at an excitation/emission wavelength 
of λ=545/590nm, respectively.52 Wells containing cells in the culture medium without 
materials were used as negative control (K-). Ethanol (96%) was added to wells that 
were used as a positive control (K+).49,53 
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1.3. Results and discussion 
 
1.3.1. Synthesized materials  
 
Figure 1.1 summarizes all synthesized and used materials and their respective 
compositions.  
 
Table 1.1 Reference and composition of materials. 
Material abbreviation Polymer matrix Antimicrobial compound 
PE Polyethylene 
 
  
PE_MeOx Polyethylene 
 
 
Oligo(2-methyl-2-oxazoline) end-capped 
with N,N-dimethyldodecylamine 
 
PE_EtOx Polyethylene 
 
 
Oligo(2-ethyl-2-oxazoline) end-capped 
with N,N-dimethyldodecylamine 
 
PE_OA Polyethylene 
 
Lavender oil (composition in Appendix 1) 
 
 
1.3.2. Materials characterization  
 
1.3.2.1. Gravimetric determination of loading 
 
All polymerizations were carried out at 115 ºC and 18 MPa during 20 h and more 24 h 
for oligomer end-capping.30,54 High density polyethylene is extremely difficult to process 
or blend, due to its high molecular weight and high degree of chain entanglement.   
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The gravimetric data were obtained by the following equation:  
 
𝑀𝑎𝑠𝑠 𝑔𝑎𝑖𝑛 (%) =
𝑊𝑡−𝑊0
𝑊0
× 100                                                 eq. 4 
 
where W0 is the initial weight of the PE sample and Wt is the weight of the modified PE 
sample after washing and drying. The reported mass gain was the mean value of six 
different samples.   
       
 
Figure 1.14 Variation of the mass gain (%) in modified PE samples for different antimicrobial compounds 
used.    
 
Observing the results for the modified PE samples with oligo(2-oxazoline)s (Figure 1.14), 
there is a decrease in the mass gain of PE samples with the increase in the size of the 
side chain of the oligo(2-oxazoline). The amount of monomer used was calculated in 
order to achieve the saturation of medium with monomer, ensuring the maximum loading 
into the PE matrix. The PE modified with oligo(2-methyl-2-oxazoline), comprising a 
methyl side chain, presents a higher mass gain comparing with PE modified with oligo(2-
ethyl-2-oxazoline), which contains an ethyl side chain. This suggests that the rate of 
diffusion through the PE matrix plays a role in the loading of the monomer, once all the 
reaction conditions were the same, the free volume of PE is identical and hence the 
larger monomers diffuse through the matrix slower than smaller ones, leading to a small 
amount of oligomer polymerized inside the PE matrix.   
In the case of PE impregnated with lavender oil, there is no previous work describing the 
supercritical-assisted impregnation in literature, so it is not possible to compare this result 
with previous data. Although, PE impregnated with lavender oil presents similar values 
of mass gain to the modified PE samples with oligo(2-oxazoline)s showing that probably 
that is the maximum amount possible to impregnate in this polyethylene matrix. 
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1.3.2.2. Morphological characterization 
 
SEM micrographs were obtained for unmodified PE, PE modified with two 2-oxazoline-
based oligomers and PE impregnated with lavender oil (see Figure 1.15).   
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Figure 1.15 SEM micrographs of surface and cross section of the unmodified PE and PE modified with 
antimicrobial compounds: PE_MeOx, PE_EtOx and PE_OA. 
 
The SEM images show that all materials present the same morphology, without changes 
after the supercritical-assisted modification. These results confirm that processing 
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material in high pressure and temperature conditions do not cause morphological 
modifications in the structure. Moreover, the presence of oligomers or compounds are 
not visible at the PE matrix surface, suggesting that the antimicrobial compounds are 
inside the PE matrix, which was swelled during the scCO2 process and back to original 
form after depressurization, confining the new compound inside and avoiding its 
leaching.46 
 
1.3.2.3. Determination of materials composition 
 
In order to confirm the success of oligomers polymerization, NMR analysis was made 
using the non-impregnated oligomers recovered from the bottom of the reactor after the 
in-situ polymerizations (see Appendix 2 and Appendix 3).30      
The effectiveness of the supercritical in-situ polymerization and impregnation procedures 
was evaluated by XPS and elementary analysis.  
  
Table 1.2 Percentage of different elements in the surface of each sample. Data obtained by XPS.   
Sample Nitrogen (%) Carbon (%) Oxygen (%) Silicon (%) 
PE 2.1 80.0 16.5 1.4 
PE_MeOx 3.7 81.9 11.7 2.7 
PE_EtOx 0.3 83.8 14.1 1.7 
PE_OA 0.9 84.4 13.0 1.6 
 
XPS is a technique able to identify and quantify the elemental composition at the surface 
region with an analysis depth of the order of 3-10 nm. Observing the results (see Table 
1.2), no significant changes were observed comparing the untreated PE with modified 
PE materials. This technique only analyses the surface, and most of this differences 
could be due to the presence of some impurities at the samples surface, which are not 
significant when considering the overall sample. 
   
Table 1.3 Percentage of different elements in each sample, evaluated by elemental analysis.  
Sample Nitrogen (%) Carbon (%) Hydrogen (%) Sulphur (%) 
PE 0.03 83.12 11.86 0 
PE_MeOx 0.12 82.92 13.58 0 
PE_EtOx 0.07 83.09 12.80 0 
PE_OA 0.06 82.54 13.43 0 
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Complementing the XPS analysis, elemental analysis based on sample combustion 
dynamics was performed. Analyzing the Table 1.3, we could notice an increase in the 
amount of nitrogen and hydrogen, confirming the introduction of a new compound 
containing these elements in its composition. Also, it is possible to see a decrease in the 
percentage of carbon (the element present in more quantity in PE), which is an expected 
result, since the addition of new compounds to the PE matrix reduces the proportion of 
this element in the overall matrix.  
  
 
1.3.2.4. Thermal properties 
 
DSC thermograms of unmodified PE, of 2-oxazoline-based oligomers synthesized 
outside the PE matrix and of modified PE samples are shown in Figure 1.16.  
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Figure 1.16 DSC thermograms of unmodified PE, of oligomers synthesized outside the PE matrix and of 
modified PE samples.    
 
The DSC of unmodified PE displays the expected single melting peak at 139 ºC. By 
analysing the thermograms, we can conclude that the presence of oligo(2-oxazoline)s 
oligomers in the PE matrix shift melting temperature (Tm) to values more close of 
oligomer Tm and also this last one disappear. It can be seen that in each thermogram 
only one Tm is present, losing the peak corresponding to the oligomer, which suggests 
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an interaction between the oligomer and PE matrix, and consequently a successfully 
impregnation. These results also suggest that the treatment with scCO2 do not change 
the degree of crystallinity compared with original PE.   
 
1.3.3.  Evaluation of the antimicrobial activity  
 
1.3.3.1. Disc diffusion  
 
In order to evaluate the susceptibility of bacteria and yeasts to the developed 
antimicrobial compounds, solutions of 100 mg/mL in water of each oligomer were placed 
in paper discs and tested for different microorganisms.  Also, lavender oil extracted using 
scCO2 was tested against the same microorganisms, without any dilution. This method 
allows a quick determination of the antimicrobial activity of compounds.  
 
Table 1.4 Antimicrobial activity evaluated by disk diffusion for different synthesized oligomers and lavender 
oil, against different gram positive and negative bacteria and yeasts. 
 Diameter of growth inhibition zone (mm) 
Microorganism MeOx EtOx Lavender oil 
E. coli DH5α 15 17 12 
S. aureus COL 20 23 23 
S. aureus ATCC 25923 29 31 22 
C. albicans PYCC 3436  29 36 10 
C. glabrata PYCC 2814 15 23 0 
 
 
From the Table 1.4 it is possible to say that the synthesized oligomers, oligo(2-methyl-
2-oxazoline) and oligo(2-ehtyl-2-oxazoline), have a significant antimicrobial activity 
against all the 5 microorganisms tested. Oligo(2-ethyl-2-oxazoline presents for all the 
microorganisms the highest growth inhibition zone. This results are in agreement with 
previous reports using similar oligomers.30 This kind of test only gives a qualitative result, 
since the limitations of the technique should be considered, such as the diffusion of the 
solution from the disk due to the viscosity or possible interactions between the sample 
and the disk. 
In the case of lavender oil, antimicrobial activity was observed against all 
microorganisms, with exception of C. glabrata. The chemical composition of lavender oil 
is reported in Appendix 1 and as expected, linalool and linalyl acetate were the main 
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components. Linalool has been reported as the component responsible for the 
yeastscidal activity and the activity of lavender oil against microorganisms could be 
depend on an additive effect of its major components; however, the contribution of minor 
constituents to the antimicrobial activity cannot be disconsidered.55 A previous study 
already reported the antimicrobial and antifungal activity of lavender oil.56 The result 
related with C. glabrata is unexpected, once the activity against yeasts is already 
reported. However there is no previous study reporting the antimicrobial activity of the 
lavender oil against this microorganism. This occurrence could be due to the previously 
mentioned limitations of the technique and a negative result can not mean the absence 
of activity and this result should be confirmed with tests performed in liquid medium.     
It is important to note that the tested compounds present antimicrobial activity against a 
multi-resistant S. aureus, which is a very promising result, since there are not many 
compounds effective against this microorganism.57  
Unfortunately, there is no zone diameter interpretative standards for the tested 
compounds, so it is not possible to evaluate if the microorganisms are susceptible, 
intermediate or resistant.  
 
1.3.3.2. Microdilution 
 
To evaluate the ability of the materials to kill bacteria and yeasts upon contact, cells 
viability after direct exposure to PE modified with antimicrobial compounds was assessed 
using E. coli, S. aureus, C. albicans and C. glabrata.   
The materials were incubated in medium containing cells and, after incubation, samples 
medium were diluted, plated and the number of colony-forming units (CFU) was counted.  
Incubation of bacteria and yeasts cells, with stirring, in the presence of the unmodified 
PE did not influence the normal growth of the E. coli, S. aureus and C. glabrata cells. 
These results are the expected, since PE in its native form does not have antimicrobial 
activity (Figure 1.17).58 However, unmodified PE killed >99.9% of the C. albicans cells (3 
log stages reduction=a reduction of 99.9%). This effect was not predictable, so other 
tests are required to explain this result, such as the use of another strain of C. albicans 
to clarify if this antimicrobial activity is only for this strain in particular or species-specific.  
The addition of 2-oxazoline-based antimicrobial oligomers to the PE matrix improved 
drastically the material antimicrobial performance. After 18 h for bacteria and 24 h for 
yeasts, the materials reduce the cells viability over 99.9%. These results are in 
accordance with previous data reported for materials comprising similar compounds 59. 
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Figure 1.17 Inhibition of E. coli, S. aureus, C. albicans and C. glabrata replication (left to right, top to bottom) 
by direct exposure to different materials with antimicrobial activity. The results are presented as the reduction 
in number of viable cells in a logarithmic scale.  
 
The presence of positive charge is an important requirement for the antimicrobial activity 
of the samples due to the mechanism of action, since the phospholipid content of 
membranes is predominantly anionic. As previous suggested, the cationic extremity of 
the oligomer should initiate electrostatic interactions with the negatively charged 
membrane of microorganisms and consequently leading to its disruption.31     
The addition of lavender oil to the PE did not improve the antimicrobial properties of the 
material. Since E. coli, S. aureus and C. albicans showed susceptibility to this compound 
in the disc diffusion technique, it is possible that something during the impregnation 
affected its activity. It is possible that the amount of oil that diffused to the matrix was 
lower than the necessary amount to kill these microorganisms, or some compounds of 
lavender oil might have partitioned differently to the scCO2 phase leading to a non-
efficient impregnation of the more active compounds, since the scCO2-assisted 
extraction was made at different conditions.55   
 
The long term stability of the samples was evaluated using the same method as 
previously, after 52 days at 60 ºC.  After this treatment, few changes in antimicrobial 
activity of the materials were noticed (see Figure 1.18). 
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Figure 1.18 Evaluation of the long term stability of samples, by assessment of the antimicrobial activity using 
the same method as before, after 52 days at 60 ºC. Killing of E. coli, S. aureus, C. albicans and C. glabrata 
(left to right, top to bottom) by direct exposure to different materials with antimicrobial activity.     
 
A loss in activity of PE_MeOx against E. coli and S. aureus was verified, suggesting that 
this compound suffered some changes during this time at these conditions that unable 
its capacity to kill these microorganisms. It is possible that the loss in activity may be due 
to degradation of oligomer or to a lower binding affinity to the bacterial cell membrane or 
to limited diffusion through the bacterial cell wall. 
On the other hand, the PE_OA material acquired antimicrobial activity against C. 
albicans and C. glabrata. This could be explained by decomposition of some compounds 
of the lavender oil, making it toxic for cells and killing them.  
The PE_EtOx did not show any variation in its antimicrobial activity, demonstrating 
stability at these conditions.         
 
1.3.3.3. Evaluation of the anti-biofouling activity 
 
Biofouling is a multistage process that starts with the formation of a biofilm in which 
microorganisms adhere to the surface. A compound that does not kill microorganisms, 
can prevent the formation of a biofilm by, for instance, changing only the materials 
hydrophilicity. In this work, we changed the materials hidrophilicity at the same time that 
some antimicrobial characteristics to the material were introduced. Even if the modified 
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material is not able to release the antimicrobial compound to the medium to avoid 
bacterial contamination, the material can be able to avoid bacterial growth and 
proliferation at the surface. In order to evaluate if PE modified with antimicrobial 
compounds presents any anti-biofouling activity, the samples used in the microdilution 
tests were placed in glutaraldehyde to fix the microorganisms, dried with ethanol and the 
surfaces were analysed by SEM.     
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Figure 1.19 SEM micrographs of surface of the PE, PE_MeOx, PE_EtOx and PE_OA after contact with E. 
coli and S. aureus.  
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The absence of biofilm formation for the material modified with oligo(2-oxazoline)s was 
already expected, once these compounds have shown a high capacity to kill these 
microorganisms in the evaluation of antimicrobial activity (Figure 1.19 and Figure 1.20) 
 
 C. albicans C. glabrata 
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Figure 1.20 SEM micrographs of surface of the PE, PE_MeOx, PE_EtOx and PE_OA after contact with C. 
albicans and C. glabrata.  
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For unmodified PE the prevention of the biofilm formation was expected only for C. 
albicans, since that PE have shown to be active against this microorganism. However, 
PE also prevented the formation of biofilm for S. aureus. None of these results for anti-
biofouling activity of unmodified polyethylene is in accordance with the literature, since 
the previous studies reported that surface of polyethylene is easily colonized by 
microorganisms.60    
In the case of polyethylene impregnated with lavender oil, despite did not present 
antimicrobial activity for any microorganism, it was effective in inhibiting biofilm formation 
for both yeasts, C. albicans and C. glabrata. These results are in accordance with 
previous reports, which have refer that lavender oil is effective against yeasts.55 The 
quantity of lavender oil that diffused to the liquid medium could be not enough to kill 
bacteria but the impregnation revealed to be enough at least to inhibit yeasts adhesion 
at the surface.  
The anti-biofouling activity of this material for S. aureus could not be assessed, since 
this sample was degraded during SEM analysis.   
     
1.3.3.4. Bactericidal or bacteriostatic 
 
In order to evaluate if the antimicrobial compounds, that have shown to be effective, 
really kill the microorganisms by destroying the membrane (bactericidal) or just prevent 
the growth of bacteria inhibiting its multiplication (bacteriostatic), a test was performed. 
In the microdilution test, no microorganisms growing were observed for polyethylene 
modified with oligo(2-oxazoline)s. In this test, medium samples of each previous well 
were taken and placed in contact with new medium, and the presence of microorganisms 
growing after 24 h was evaluated.         
 
Table 1.5 Evaluation of the presence of growing using samples of medium obtained in microdilution test in 
new medium.   
 PE PE_MeOx PE_EtOx 
E. coli - No No 
S. aureus - No No 
C. albicans Yes  No No 
C. glabrata - No No 
 
Observing the growing results (Table 1.5), it is possible to conclude that the antimicrobial 
compounds are bactericidal, once there is absence of microorganisms growing when 
samples of medium with no growing in the microdilution test were placed in new medium 
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and stored at 37oC during 24 h. These results are in accordance with literature about the 
possible mechanism of action of similar polymers, suggesting that the main target of 
these agents is the microorganisms membrane, causing disruption by the linear end-
capper group.30,61,62 In the case of PE active against C. albicans, the activity is 
bacteriostatic, just inhibiting the multiplication in the presence of the compound. As 
previously mentioned, this result is not in accordance with previous reports about 
antimicrobial activity of pure polyethylene.58     
 
1.3.4.  Biocompatibility tests 
 
In order to evaluate the applicability of these new materials for biomedical applications, 
the cytotoxicity was studied. Due to the need of specialized laboratories to do these tests, 
different materials were tested in different laboratories and different methodologies were 
used.  
 
1.3.4.1. Polyethylene impregnated with lavender oil  
 
Fibroblast cells were seeded at the same initial density in the 96-well plates, with and 
without sample materials to assess the cytotoxicity. After 48 h, cell adhesion and 
proliferation was visualized using an inverted light microscope (Figure 1.21). Cells grew 
in the vicinity of the both materials, PE_OA and PE, and in the negative control. In the 
positive control, no cell adhesion or proliferation was observed and a typical spherical 
shape of dead cells could be observed.       
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Figure 1.21 Photomicrographs of fibroblast cells after being in contact with PE_OA material (a) and untreated 
PE (b). Negative control (c), without addition of any component, and positive control (d), with addition of 
ethanol, is also presented.   
 
To further evaluate the biocompatibility of the materials, a resazurin assay was also 
performed (Figure 1.22). This test did not show a significant difference between cells 
exposed to materials and the negative control after 48 h of incubation, suggesting that 
the materials did not affect cell viability and do not have any cytotoxic effect.  
 
Figure 1.22 Cellular activity measured by the resazurin assay. Fibroblast cells in the presence of PE_OA 
material and untreated PE, negative control without addition of any component and positive control with 
addition of ethanol. 
 
1.3.4.2. Polyethylene impregnated with 2-substituted oxazolines 
 
The cytotoxicity of PE_MeOx and PE_EtOx materials, untreated PE and MeOx and EtOx 
was characterized through in vitro studies using fibroblast cells and human colon 
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carcinoma HCT-116 cells after 1 h and 24 h of incubation. The analysis of the results 
was performed qualitatively and quantitatively.    
 
 
 
 
Figure 1.23 Visual observation of the microplates 45 min after addition of MTS for Fibroblast (above) and 
HTC-116 (bellow) after 1 h and 24 h of incubation, in the presence of PE_MeOx and PE_EtOx materials, 
untreated PE and MeOx and EtOx solutions and the negative control, respectively.  
 
 
Figure 1.24 Photomicrographs of fibroblast cells after being seeded in contact with PE_MeOx (a), PE_EtOx 
(b), untreated PE (c), MeOx (d) and EtOx (e) during 24 h. Negative control (f), without addition of any 
component, is also presented.   
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By visual observation of the microplates (Figure 1.23) and photomicrographs of fibroblast 
cells (Figure 1.24) showing the cells shape, it is possible to infer about the 
biocompatibility of the tested materials and oligomers. The presence of reference color 
of the compound formed after reduction of the MTS reagent by the viable cells and the 
cells elongated shape give us a qualitative analysis suggesting any presence of 
cytotoxicity.     
The quantitative analysis was made, by measuring the absorbance at 490 nm and the 
cell viability were normalized relatively to the negative control samples. 
  
 
Figure 1.25 Cellular activity measured by the MTS assay. Fibroblast (left) and HTC-116 (right) after 1 h of 
incubation in the presence of PE_MeOx and PE_EtOx materials, untreated PE and MeOx and EtOx 
solutions.  
 
   
Figure 1.26 Cellular activity measured by the MTS assay. Fibroblast (left) and HTC-116 (right) after 24 h of 
incubation in the presence of PE_MeOx and PE_EtOx materials, untreated PE and MeOx and EtOx 
solutions.  
 
The results of the cytotoxicity evaluations after 1 h and 24 h of incubation (Figure 1.25) 
indicated that tested materials and oligomers displayed no cytotoxic behavior. These 
data of MeOx and EtOx oligomers are in accordance with the literature.30 Also the results 
for PE are in agreement with previous studies reported.63 The blend of compounds did 
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not affect their biocompatible behavior, showing a satisfactory biocompatibility of the 
developed materials.      
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1.4. Conclusion 
 
In order to develop self-disinfecting polyethylene-based vaginal applicators, a 
modification with oligo(2-oxazoline)s and lavender oil was investigated to confer 
antimicrobial properties to the material. The in-situ polymerization of 2-substituted 
oxazolines via CROP using a scCO2-assisted process and the end-capping with a 
quaternary amine led to a presence of antimicrobial oligomers inside the polyethylene 
matrix. Furthermore, polyethylene matrix was impregnated with lavender oil in order to 
confer the oil properties to the polymer. The presence of compounds in the matrix after 
washing was confirmed using XPS, elemental analysis and DSC. The ability to kill 
bacteria and yeasts upon contact was verified against E. coli, S. aureus, C. albicans and 
C. glabrata. Probably because of electrostatic interactions with the membrane of 
microorganisms and its disruption; polyethylene modified with oligo(2-oxazoline)s 
present a biocidal behavior, reducing the cell viability over 99.9%. The ethyl-oxazoline-
based material remains biologically active against all microorganisms for at least 52 
days.     
On the other hand, polyethylene modified with lavender oil did not show effectiveness 
against the tested microorganisms. The reason for this extremely low activity could be 
the non-efficient impregnation of more active compounds of lavender oil, disabling the 
antimicrobial property of the material.    
Moreover, direct contact cytotoxicity tests revealed that the polyethylene modified 
materials are highly biocompatible, do not showing any cytotoxic response.  
The prepared polyethylene modified with oligo(2-oxazoline)s materials were more 
efficient than the polyethylene modified with lavender oil.  
The oligo(2-oxazoline)s-modified polyethylene represents a promising material for 
biomedical applications due to the antimicrobial activity and biocompatibility. The use of 
such materials could minimize the impact of poor cleaning and disinfecting practices 
during usage. 
For the industrial applications point of view of this antimicrobial compounds in the vaginal 
applicators, the direct incorporation of the active polymer during the device 
manufacturing process could be tested, in order to reduce the steps and the associated 
costs. 
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Chapter 2: Surface modification to reduce powder retention 
in a Dry Powder Inhaler 
 
 
2.1. Introduction 
 
This section describes an approach for inhaler’s surface modification in order to reduce 
the powder retention and improve the lung delivery. 
 
2.1.1. Inhalers 
 
The respiratory tract is an attractive delivery route, with global drug delivery market size 
about 30%. The major advantages of pulmonary drug delivery include avoiding the 
severe conditions of the gastro intestinal, non-invasive path of administration, fast drug 
absorption and action, and local treatment of specific diseases.64 
Novel inhaled therapeutics comprising vaccines, antibiotics and anti-hypertensives, have 
conducted to innovations in designing suitable delivery systems. These developing 
design technologies are in exigent demand to ensure high aerosolisation performance, 
consistent efficacy and satisfactory patient adherence. 
The pressurised metered dose inhalers (pMDI) has been preferred by patients and 
healthcare professionals for the treatment of asthma and COPD since its introduction in 
1956.65 The active ingredients in pMDI inhalers are suspended or dissolved in a 
propellant, a mixture of propellants, or a mixture of solvents and they are delivered via a 
compact pressurized aerosol distributor. MDIs require the user to coordinate pressing 
down the canister and inhaling the drug. Another disadvantage of using pMDIs is the 
propellant, normally chlorofluorocarbon (CFC), which has been shown to deplete the 
ozone layer. Hydrofluoroalkane (HFA) is now used and can cause the inhaler to be more 
expensive.66 
Nebulisers are useful for treatment of respiratory diseases as asthma, COPD and cystic 
fibrosis (CF).67 They generate an inhalable drug aerosol from a solution or suspension. 
The most used nebuliser type is the jet nebuliser, which generates aerosols from the 
liquid drug using a source of compressed gas. Although it is relatively inexpensive, the 
use jet nebulisers requires long-time treatment, the air compressors are noisy and bulky, 
and expensive medications are missed in considerable residual volumes.68  
Alternatively, dry powder inhalers (DPIs) have become highly favourable for delivering 
high-dose and single-dose drugs with the aid of innovative particle engineering. The 
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development and use of DPIs have initially been focused on diseases like asthma and 
COPD. The pulmonary route for these applications offers direct access to the site of 
action and leads to a rapid onset of action. This decreases the total dose to be given 
substantially compared to oral administration.69  
Advantages of DPIs compared with other ways of aerosolization include stable 
formulations, low cost, automatic coordination between inhalation and dose delivery, and 
a wide variety of design attributes that can be used to enhance performance.70 However, 
drug delivery to the lungs from DPI is known to be inefficient. Is a much greener 
alternative over the pMDI in terms of stability and avoidance of ozone-depleting and 
global warming propellants,66 but its delivery efficiency is not high. Therefore, there is a 
growing need to enhance and improve the performance of today’s devices in order to 
increase the drug that reaches the lungs, from both an efficiency and cost-containment 
point-of-view. Examples of different inhaler can be seen in Figure 2.1.   
   
 
Figure 2.1 Examples of pressurised metered dose inhaler (pMDI), nebuliser and dry powder inhaler (DPIs), 
respectively.71–73    
 
2.1.2. Dry powder inhalers 
 
Dry powder inhaler (DPI) formulations are typically binary mixtures comprising a 
micronized active agent and a carrier particle population that constitutes the bulk of the 
formulation (>95% w/w). When a patient inhales through a DPI, the energy resulting from 
their inspiratory effort fluidizes the powdered dose, detaching a fraction of the drug from 
the larger carrier particles and depositing it in the deep lung where it applies its 
therapeutic effect.74 In DPI, the formulation is placed between the inlet and outlet of an 
air passage and air is inspired. Difficulties can arise in producing sufficient air flow 
through the device to entrain the drug and carry it as far as possible into the patients’ 
lung. Air turbulence created through the device and oral cavity dictates, in part, the 
amount of drug that reaches the lower airways. 
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In evaluation of existing or future DPI devices, the following key factors should be 
considered to ensure ideal dose delivery: the device’s internal resistance, uniformity of 
the emitted dose, and aerodynamic particle size distribution.75 The higher the resistance, 
the harder it is to generate inspiratory flow great enough to achieve the maximum dose 
from the inhaler. An ideal DPI would have a low internal resistance and deliver a high 
respirable fraction, even at low inspiratory flow.76  
 
The aim of the current study was to compare four different inhalers’ prototypes with 
different needle’s diameters, and evaluate the device resistance and emitted dose of 
lactose and Foradil.  
 
2.1.3. Reduction of powder retention 
 
Capsule-based DPIs can be limited by powder retention in the capsule and device, which 
leads to a reduction in the emitted dose. Although the fraction of drug remaining in the 
mouthpiece is generally between13–20% (determined via in vitro aerosolization tests), 
in some inhalers, it could be nearly 30–50%.77 This can be due to mechanical impaction 
of the powder on the device surface and/or electrostatic charge created during powder 
dispersion. As pharmaceutical solids and most DPI devices are insulative, the generated 
electrostatic charge is difficult to dissipate.78 Therefore, modification of device surface 
characteristics may successfully reduce the device retention by reducing attractive 
forces. 
Pharmaceutical lubricants like magnesium stearate (MgSt) and leucine have a low 
surface energy, which can minimize adhesion and friction between particle–particle or 
particle–inhaler surface.79 MgSt is an extensively used lubricant for tabletting, and is an 
approved excipient for inhalation products by the US FDA. Given its recognised safety 
profiles, coating of MgSt and leucine on inhalable particles has been studied extensively 
to improve device retention and aerosolisation by reducing particle surface energy and 
powder cohesion.80–82 In recent years, a new alternative approach of coating the internal 
surfaces of capsules and DPI devices with MgSt, to reduce drug retention have been 
proposed. For the Aerolizer, coating of capsules and inhalers with 0.3 mg/mL of MgSt, 
significantly reduced capsule and inhaler retentions by 79 and 69%, respectively, 
compared to the uncoated counterparts. The Rotahaler also showed a considerable 
reduction in capsule (by 73%) and device retention (by 53%). For both inhalers, reduced 
capsule and device retentions lead to a significantly higher fine particle doses.83 
In another report, the surface of a newly designed CC-3D resin inhaler and HPMC 
capsules were coated with a low surface energy polytetrafluoroethylene suspension.84 
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The capsule, capsule chamber and mouthpiece retention were considerably reduced 
from 14.1 to 7.3%, 8.8 to 2.2% and 13.2 to 9.1%, respectively. 
These studies have shown the efficacy of surface coating to reduce powder retention in 
capsule and inhaler devices.  
In this study, in the inhaler with best performance, with the results of the device 
resistance and emitted dose, was coated with a force control agent in order to reduce 
the powder retention in the inhaler’s nozzle.  
 
2.1.4. ScCO2-assisted drying 
 
Supercritical drying is a process where the liquid in a substance is transformed into gas 
in the absence of surface tension and capillary stress. The unique solvent tuneability of 
supercritical fluids, from gas-like to liquid-like properties, offers the interesting possibility 
of precise control over the processing conditions, leading to new applications. The use 
of supercritical fluids technology in the drying process of the developed materials can 
lead to highly dried and pure products, due to the high diffusivity of CO2, the fluid phase 
can easily reach the bulk of the structure. The scCO2 also could be used to dry the wetted 
materials by selectively extracting the solvent conducing to a thin film of the coating 
material. Due to the high solubility of ethanol in carbon dioxide, drying of the materials 
can be successfully obtained.85  
 
  
45 
 
2.2. Experimental  
 
2.2.1. Materials 
 
DPIs were manufactured by BeyonDevices. Four different DPIs with different needle’s 
diameters of 1.25, 1.5, 1.5 pencil and 2 mm (Figure 2.2) were used. Magnesium stearate 
was purchased from Sigma-Aldrich. Lactose with two different particle sizes (MM50 and 
MM3) was purchased from Micro-Sphere S.A.  
 
              
Figure 2.2 BeyonDevices’ Inhaler86 and schematic representation of different needle’s diameters (a) 1.5 
pencil, (b) 1.25, (c) 1.5 and (d) 2 mm.  
 
 
2.2.2. Characterization of the different Dry Powder Inhalers 
 
2.2.2.1. Experimental apparatus  
 
Figure 2.3 shows a schematic representation of the DUSA apparatus, used for the flux 
tests.  
 
 
Figure 2.3 Schematic representation of the DUSA apparatus, adapted from Copley Scientific.87 
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2.2.2.2. Flux tests 
 
The flow rates of all four devices were obtained using a Copley Dose Uniformity 
Sampling Apparatus (DUSA, Copley Scientific), Copley critical flow controller TPK 
(Copley Scientific), and vacuum pump (Copley Scientific). For this assembly, the DUSA 
with the mouthpiece adapter was connected to the TPK, and a vacuum source. The 
pressure measurement port on the DUSA was connected to the TPK to enable 
measurement of the device flow rate at a defined pressure. An empty capsule was 
inserted into the device, and the pressure was adjusted to achieve pressures between 1 
and 4 KPa. In this way, the flow rate was determined disconnecting the mouthpiece 
adapter and connecting a flow meter. The specific resistance (R) was then calculated 
from the flow (Q) and the pressure drop (∆P) using the equation: 
 
                                                  eq. 5 
 
 
2.2.2.3. Uniformity of delivered dose 
 
For delivered dose uniformity testing, the apparatus setup presented in Figure 2.3 was 
used. Delivered dose uniformity experiments were carried out at 4 KPa for each DPI.88 
Loaded capsules, with 0.080 g of lactose, were placed in a DPI and adapted in a 
mouthpiece adaptor. The vacuum pump was turn on during a specific time calculated 
according with the flow rate of inhaler using the equation 6.  The emitted dose was 
calculated by the difference between the weight of inhaler and capsule before and after 
the assay. Tests were performed for the two different lactoses and in each assay 10 
capsules were used.  
 
𝑡(𝑠) =
4 (𝐿)∗60 (𝑠)
𝐶𝑎𝑢𝑑𝑎𝑙 (𝐿/𝑚𝑖𝑛)
                                                  eq. 6 
 
2.2.3. Modification of Dry Power Inhaler   
 
2.2.3.1. Coating with magnesium stearate  
 
The inhaler was coated with ethanol-based magnesium stearate suspension (0.3 g/mL) 
via painting and left to dry at room temperature during 2 h. 
 
(∆𝑃)0.5 = 𝑄. 𝑅 
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2.2.3.2. Drying of DPI with scCO2 
 
The drying of coated inhaler was performed in a high-pressure cell with a flow of fresh 
scCO2 during 2 h at 40oC and 10 MPa.  
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2.3. Results and discussion 
 
2.3.1. Different Dry Powder Inhalers 
 
2.3.1.1. Flux tests 
 
In order to evaluate which inhaler had the best performance in coating and reducing the 
powder retention, flux and uniformity of delivered dose tests were performed.  
The emitted dose from a DPI can be inhalation flow dependent so information about the 
resistance of these devices is necessary. Typically, significant differences in the specific 
resistance of test and reference DPIs may lead to significant differences in drug delivery 
performance.89 The internal “force” required for fluidization and disaggregation is 
dependent on the resistance of the DPI device and the patient's inspiratory effort.90 
 
 
Figure 2.4 Relationship between pressure and flow rate for four different DPIs. 
 
There was almost no difference between the flows through the four different inhalation 
devices at the different pressure drops (see Figure 2.4). From these measured flows, a 
mean device resistance of 0.06 cmH2O0.5/(L/min) for the inhalers was obtained. 
As shown in the present study, all inhalers can be regarded as low-resistance devices, 
with values at the lower end of the range observed with most devices, and inspiratory 
flows of >60 L/min are typically achieved by more than 90% of asthmatic patients.91 
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Devices with high internal resistance may be problematic for patients with severe airway 
obstruction (i.e., acute asthma or COPD), children, and the elderly, who may have 
difficulty in exerting sufficient inspiratory effort. 
According with a previous study,90 in the case of 'maximum' effort the pressure drop 
developed by the chest is constant and that the low device pressure drops at resistances 
values less than 0.05 cmH2O0.5/(L/min) are the result of an increasing portion of the 
pressure drop being deployed across the airways. At high resistance the inhaled flow 
rate will be low and the powder device can afford to generate a slightly coarser aerosol 
and still ensure penetration into the conducting and lower airways. However, patient 
'comfort' is also an important factor and there was some subjective evidence in the above 
study, as evidenced by unsolicited comments from the volunteers, that resistances 
greater than about 0.1 cmH2O0.5/(L/min) were 'uncomfortable'. This is probably due to 
the increased inhalation time and the need for a longer sustained effort with higher 
resistances.92 
 
2.3.1.2. Uniformity of delivered dose 
 
The first test of delivered dose was made using the inhalers with opposite needles and 
the two different lactose with different particle’s size.  
 
Table 2.1 Emitted dose for the four different inhalers and two different lactoses, with the needles in opposite 
position.     
Inhaler Emitted dose (%) 
MM50 
 
MM3 
1.25 mm 9.4 4.5 
1.5 mm 0.9 3.1 
1.5 mm pencil 25.2 1.6 
2 mm 51.1 3.7 
 
As we can see by the results (see Table 2.1), the emitted dose was very low in this 
conditions, especially for the lactose MM3, with largest size, where all needles present 
an emission in the same order. This result could be explained by the shortest space 
between two needles in the inhaler and also by the humidity present in the lactose MM3, 
which difficults the exit of powder from the capsule. Due to these results, the following 
tests were only made for the lactose MM50. Comparing the emission between needles 
for lactose MM50, the needle with higher diameter showed the best emitted dose, 
followed by the needle with 1.5 mm pencil. The lowest emission is obtained using a 
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needle with 1.5 mm, however it was expected that the lowest result would be obtained 
for the needle with 1.25 mm, since the area to powder crossing was smaller. This result 
could be explained by the spacing between the in and out needles, that is a little bit 
smaller for needle with 1.5 mm. Besides this, there is always an amount of powder that 
is lost in the inhaler nozzle’s.       
 
Table 2.2 Emitted dose for the four different inhalers and lactose MM50, with the needles in same position.   
Inhaler Emitted dose (%) 
MM50 
1.25 mm 24.9 
1.5 mm 7.5 
1.5 mm pencil 20.3 
2 mm 68.9 
 
By changing the orientation of the needles (Table 2.2), it was possible to observe an 
increase in the emitted dose for all different inhalers, with exception for the inhaler with 
a pencil needle. This kind of needle presents a lateral hole in contrast with the other ones 
that present the hole at the extremity (see Figure 2.2). By this way, it is possible to 
confirm that the air flow is more effective, leading to a better transportation of the powder. 
As expected, the needle with highest diameter presents best results, with an emitted 
dose of 68.9%.  Thus, this was the inhaler chosen for the tests with a real formulation.     
 
Foradil consists of a dry powder formulation of formoterol fumarate intended for oral 
inhalation with an inhaler. The inhalation powder is packaged in clear hard gelatin 
capsules. Each capsule contains a dry powder blend of 12 µg of formoterol fumarate and 
25 mg of lactose as a carrier. This formulation was used as model formulation in the 
uniformity emitted dose tests.  
 
Table 2.3 Emitted dose for the inhaler with needle diameter’s of 2 mm and Foradil, with the needles in 
same position.   
Inhaler Emitted dose (%) 
2 mm 30.0 
 
 
The emitted dose (Table 2.3) obtained for this formulation using the inhaler with 2 mm 
needle was lower than obtained for lactose. This result could be explained by the amount 
of powder in the capsule, which was 0.080 g for lactose and 0.025 g for Foradil, 
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confirming the smaller amount of powder available to be emitted, and also the smaller 
amount present between the two needles, where the air pass and drag the powder.  
The emitted dose from the Foradil obtained in this study is lower than previous reported 
studies (82%93 and 90%94 at flows of 60 L/min).  
 
2.3.2. Comparison of optimized device performance 
 
2.3.2.1. Powder retention  
 
MgSt is a commonly-used force control agent and was applied to the inside surface of 
the inhaler nozzle’s to minimize powder retention and increase the fraction entering the 
lungs.   
 
Table 2.4 Emitted dose for the inhaler with needle diameter’s of 2 mm, with the inside surface of the inhaler 
nozzle’s coated with MgSt, using lactose MM50 and the needles in same position.   
Inhaler Emitted dose (%) 
2 mm 71.3  
 
 
Table 2.4 shows the emitted dose for the inhaler with the inside surface nozzle’s coated 
with MgSt and needle diameter’s of 2 mm, using lactose MM50 and the needles in same 
position. As can be seen, the powder retention decreased. This could be due to the 
reduced adhesion between the powder and the inhaler wall which brought amount much 
improved flow properties.95         
 
Table 2.5 Emitted dose for the inhaler with needle diameter’s of 2 mm, with the inside surface of the inhaler 
nozzle’s coated with MgSt, using Foradil and the needles in same position.   
Inhaler Emitted dose (%) 
2 mm 33,7 
 
 
Using the same idea, the emitted dose for Foradil also increases (Table 2.5), as 
expected. In order to further increase the emitted dose, the capsule could also be coated 
with MgSt, to reduce the powder that stays in the capsule walls. However, this value is 
still lower than that obtained in other reported studies in literature for this formulation 
using other inhalers.94   
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2.4. Conclusion 
 
In order to evaluate the performance of dry powder inhalers with different needles, 
internal resistance and emitted dose with lactose was tested. The internal device 
resistance was similar for all inhalers and the mean value was 0.06 cmH2O0.5/(L/min), 
regarding the inhalers as low-resistance devices with inspiratory flow above 60 L/min. 
The best results for emitted dose were observed for needles in the same orientation, and 
the higher emitted dose was obtained using a 2 mm needle, the higher diameter tested, 
where 68.9% of the lactose in the capsule was emitted.     
A coating of inhaler’s nozzle with pharmaceutically acceptable force-control agent to 
reduce drug retention was developed in the previous best inhaler. Magnesium stearate 
was painted in the internal surface of the inhaler and dried with supercritical carbon 
dioxide in order to remove all solvent.This coating minimized the adhesion between the 
drug particles and the internal surfaces of the DPI, which increased the emitted dose by 
2.4% for lactose and 3.7% for Foradil. The increase in inhaled dose result in enhanced 
therapeutic benefits, and in reduction of production coasts.  
Future uptake of this technology by industry could be via direct incorporation of the 
surface modifier into the device manufacturing process. 
The tested inhalers need some improvements in order to increase the emitted dose, such 
as changes in the internal design, reduction in the air inlets or change the design of 
needles, since the powder has some difficult in through the needles and reach the 
nozzle.    
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Final conclusions  
 
The development of a master thesis in collaboration with a company is an important 
feature in the improvement of the ability to analyze problems from a research perspective 
keeping in mind the constraints and limitations of the real industry, realizing what creates 
a real value for the company.  
The present work has successfully demonstrated the possibility of improving devices 
from the real market using the academic knowledge and technologies available in the 
host laboratory.   
As future goals, it will be interesting to test the direct application of these modifications 
in the manufacturing process of the devices. Investigation of other kind of modifications 
that confer additional properties could be an additional useful feature of such medical 
devices. Regarding the vaginal applicator and inhaler, the improvement of the sliding 
factor, the mucoadhesion ability, the drug residence time or powder flowability are some 
examples of promising studies that could bring further value to the devices.    
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Appendix section  
 
Appendix 1 Composition of Lavender essential oil obtained by scC02 extraction (% calculated by area 
integration). 
Compound Composition (%) 
Trans-β-ocimene 3.99 
Cis-β-ocimene 5.80 
α-ocimene 1.28 
1-octen-3-yl acetate 2.84 
Linalool 15.99 
Linalyl acetate 36.02 
Farnesene 0.19 
β-Caryophyllen 6.10 
α-terpeniol 1.17 
Lavandulyl acetate 5.86 
Germancrene 3.41 
Lavandulol 1.00 
Fenchol <0.1 
Borneol 0.86 
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Appendix 2 1H-NMR spectrum (400 MHz, D2O) of MeOx. 
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Appendix 3 1H-NMR spectrum (400 MHz, D2O) of EtOx. 
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